{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Neuroendocrine+Tumor+%28pNET%29&page=2",
    "query": {
      "condition": "Pancreatic Neuroendocrine Tumor (pNET)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pancreatic+Neuroendocrine+Tumor+%28pNET%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T16:59:22.584Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06943755",
      "title": "Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pancreatic Neuroendocrine Tumor (pNET)",
        "Extra-Pancreatic Neuroendocrine Tumor (epNET)"
      ],
      "interventions": [
        {
          "name": "Zanzalintinib",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 440,
      "start_date": "2025-07-21",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06943755"
    },
    {
      "nct_id": "NCT01465659",
      "title": "Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Alpha Cell Carcinoma",
        "Pancreatic Beta Islet Cell Carcinoma",
        "Pancreatic Delta Cell Carcinoma",
        "Pancreatic G-cell Carcinoma",
        "Recurrent Islet Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "pazopanib hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2011-12-12",
      "completion_date": "2021-01-27",
      "has_results": true,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01465659"
    },
    {
      "nct_id": "NCT03048266",
      "title": "Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Endocrine Neoplasia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 629,
      "start_date": "2015-11-05",
      "completion_date": "2026-11-01",
      "has_results": false,
      "last_update_posted_date": "2019-05-23",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03048266"
    },
    {
      "nct_id": "NCT02549937",
      "title": "A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "surufatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hutchmed",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2015-11",
      "completion_date": "2023-06-02",
      "has_results": true,
      "last_update_posted_date": "2024-07-10",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Denver, Colorado • Sarasota, Florida + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02549937"
    },
    {
      "nct_id": "NCT01658436",
      "title": "BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neuroendocrine Tumors (pNET)"
      ],
      "interventions": [
        {
          "name": "BEZ235 (Stage 1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2012-11",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-05-02",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 4,
      "location_summary": "Indianapolis, Indiana • Boston, Massachusetts • The Bronx, New York + 1 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01658436"
    },
    {
      "nct_id": "NCT02110563",
      "title": "Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Multiple Myeloma",
        "Non-Hodgkins Lymphoma",
        "Pancreatic Neuroendocrine Tumors",
        "PNET",
        "NHL"
      ],
      "interventions": [
        {
          "name": "DCR-MYC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2014-04",
      "completion_date": "2016-11-03",
      "has_results": false,
      "last_update_posted_date": "2024-07-11",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02110563"
    },
    {
      "nct_id": "NCT06881992",
      "title": "A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Tumor Hyperinsulinism (Tumor HI)"
      ],
      "interventions": [
        {
          "name": "Ersodetug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rezolute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2025-04-16",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-18",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 8,
      "location_summary": "Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06881992"
    },
    {
      "nct_id": "NCT03043508",
      "title": "Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Genetic Mutation",
        "MEN1"
      ],
      "interventions": [
        {
          "name": "Chart Review",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2015-04-10",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2019-05-23",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03043508"
    },
    {
      "nct_id": "NCT01628913",
      "title": "Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Neuroendocrine Tumors (pNET)"
      ],
      "interventions": [
        {
          "name": "BEZ235",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2012-10",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-04-07",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Lexington, Kentucky + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01628913"
    },
    {
      "nct_id": "NCT03053999",
      "title": "Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Endocrine Neoplasia",
        "Pancreatic Neuroendocrine Tumors",
        "Hyperparathyroidism"
      ],
      "interventions": [
        {
          "name": "Genome Sequencing",
          "type": "OTHER"
        },
        {
          "name": "Data Review",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 53,
      "start_date": "2012-10-09",
      "completion_date": "2023-10",
      "has_results": false,
      "last_update_posted_date": "2019-09-12",
      "last_synced_at": "2026-06-25T16:59:22.584Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03053999"
    }
  ]
}